智通财经APP讯，山东新华制药股份(00719)发布公告，近日，该公司收到国家药品监督管理局核准签发的普瑞巴林口服溶液(以下简称“本品”)《药品注册证书》。
普瑞巴林用于带状疱疹后神经痛、纤维肌痛、成人部分性癫痫发作的添加治疗。普瑞巴林口服溶液是《国家基本医疗保险、工伤保险和生育保险药品目录》(2024年版)乙类品种，根据有关统计数据显示，2023年中国公立医疗机构普瑞巴林制剂销售额约为人民币6.24亿元。
新华制药的普瑞巴林口服溶液于2025年4月取得药品注册证书，该产品的获批上市将进一步丰富公司产品结构，提高市场竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.